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Multiple genetic abnormalities will have occurred in advanced cervical cancer and multiple targeting is likely to be needed to
control tumor growth. To date, dominant therapeutic targets under scrutiny for cervical cancer treatment have been EGFR path-
way and angiogenesis inhibition as well as anti-HPV vaccines. The potentially most eﬀective targets to be blocked may be
downstream from the membrane receptor or at the level of the nucleus. Alterations of the pathways involved in DNA repair and
in checkpoint activations, as well as the speciﬁc site of HPV genome integration, appear worth assessing. For genetic mutational
analysis, complete exon sequencing may become the norm in the future but at this stage frequent mutations (that matter) can be
veriﬁed by PCR analysis. A precise documentation of relevant alterations of a large spectrum of protein biomarkers can be carried
out by reverse phase protein array (RPPA) or by multiplex analysis. Clinical decision-making on the drug(s) of choice as a function
of the biological alteration will need input from bio-informatics platforms as well as novel statistical designs. Endpoints are yet
to be deﬁned such as the loss (or reappearance) of a predictive biomarker. Single or dual targeting needs to be explored ﬁrst in
relevant preclinical animal and in xenograft models prior to clinical deployment.
1. Inequalityin CervicalCancer Incidence and
MortalityinEurope
In economically developed countries with adequate screen-
ing practices the incidence and mortality rates of cervical ca-
ncer have been stable over the last 7 years ([1]a n dBM o n k
(IGCS meeting, Prague 2010)) with a low mortality-to-inci-
dence ratio (< than 0.3)). The mortality remains; however,
high (ratio of 0.8) in populations with inadequate or absent
screening practices [2]. In Europe, the age standardised inci-
dence of invasive cervical cancers (all stages) was estimated
for 2004 to be 10 per 100.000 women-years. These statistics
are from the “earlier” 15 member states of the European Un-
ion (EU), situated in West and South Europe. According to
recent statistics, there remains a manifest disparity in inci-
dence and mortality rates of cervical cancer across the ex-
tended EU of 27 member states. Incidence rates as high as 17
per 100000 women-years have been quoted for the ten new
member states that joined the EU in 2004 and are located
predominantly in Central and Eastern Europe. In Bulgaria
and Romania [3], the two most recent member states, that
acceded to the EU in 2007, rates were still higher with an
age-standardised incidence recorded in 2004 of respectively
20, and 22 per 100000. The mortality of cervical cancer in
Romania is approximately twelve times higher compared to
that of Finland, the country in Europe with the lowest cer-
vical cancer burden at present [4].
2. State of the Art in the Management of
Advanced Stage CervicalCarcinoma
While early stage localized cervical cancer can most often be
treated by surgical resection only and has excellent survival
statistics, the presence of lymph node or parametrial involve-
ment calls for chemotherapy and radiotherapy, most often in
association.2 ISRN Oncology
Major international groups such as the GOG (gynaeco-
logical oncology group) and the EORTC (European organi-
sation for research and treatment of cancer) as well as many
national groups have been instrumental in the development
of the present standard of care.
2.1. Evidence—Based Present Standard of Care for Stages IB2-
III Disease. Concurrent chemoradiation with a platinum-
based agent is the recommended standard of care for locally
advanced cervical cancer of stages IB2 to III. This standard
has been developed through a successive series of clinical
trials culminating in the GOG 120 trial published by Rose
et al. [5] in the NEJM in 1999. Further trials, adding 5-FU
(GOG 165) or Hemoglobin support (GOG 191), did not
furtherimproveonthisstandard.Morerecently,theaddition
of gemcitabine to the standard chemo-radiation showed a
smallbutsigniﬁcantbeneﬁtinsurvival(P = 0.022);however,
it cannot be ruled out that the higher eﬃcacy may be con-
founded by two additional cycles of adjuvant chemotherapy.
Currently,asigniﬁcantlyincreasedhematologicanddigestive
tracttoxicityblocksbroadimplementationofsuchaprotocol
(Due˜ nas-Gonz´ alez A et al. JCO 2009 [A 5507]).
2.2. Outcome of Stage 1B2 to III Cervical Cancer Patients Who
Are Not in Complete Remission following Best Standard of
Care. In a retrospective review of patients treated between
2003 and 2006 at Institut Gustave-Roussy, the outcome
for patients treated for cervical cancer was poor for those
who, following initial chemo-radiation, had not achieved a
complete histological remission in either the hysterectomy
specimen or in their lymph nodes. Patients died at a median
timeintervalof11monthsaftersurgery(range3–21months)
andfurthersurgerydidnotimprovetheoutcome[6].Similar
data have been published by a group from Montpellier [7].
Forpatients whofailﬁrst-linetherapy,subsequentcours-
es of chemotherapy are even less eﬀective. Despite treatment
with cisplatin or cisplatin and paclitaxel, the median survival
time [8] of stage IV or of recurrent disease patients in GOG
protocol 169 was approximately 8-9 months. There was no
diﬀerence between groups, and only 15–20 percent of pa-
tients remained alive at 18–20-month followup. The pallia-
tive care is complex and carries a heavy toll on health resou-
rces but foremost on patients and on their families.
2.3. Ongoing Trials to Improve Standard of Care of Stage Ib–III
Cervical Cancer. Ongoing, recently started or soon to start
phase III trials with a “classical design” ask questions on the
beneﬁt of enhancing the radio chemotherapy sequence. Of
note are the following.
(i) A presently ongoing phase III protocol (GOG 219)
that compares standard radio chemotherapy with
the addition or not of TPZ (tirapazamine), a radio-
enhancing agent, testing the eﬀect of increased free
radical formation at the tumour site.
(ii) In a randomized trial within the EORTC Gynae-On-
cology Group (EORTC 55994) the outcome of neo-
adjuvant chemotherapy followed by radical surgery
is being compared to primary chemo-radiation for
stages Ib2–IIb. Currently over 500 patients have been
randomized.
(iii) The OUTBACK trial (ANZGOG) evaluating the ef-
fect of 4 additional cycles of adjuvant paclitaxel and
carboplatin (IB2-IV) to standard radio chemother-
apy.
(iv) The INTERLACE trial (NCRI) is in development and
aims to test the addition of neoadjuvant chemother-
apy with paclitaxel and carboplatin prior to chemo-
radiation.
To our knowledge there are presently no ongoing large phase
3 trials in cervical cancer which involve-so-called “targeted”
biological reagents with the exception of bevacizumab (NSC
704865).Twophase2trialsarepresentlyongoinginstageIb–
III cervical cancers, involving cetuximab in association with
radiation and cisplatin. In France a multicentre randomized
phase 2 trial (CETUXICOL n = 76) evaluating cetuximab
(CTX) in ﬁrst-line treatment in association with chemora-
diotherapy hasbeeninitiated byInstitutCurie, ininteraction
with the national French group F´ ed´ egyn. (The following
French Cancer Centres participated in this trial: Bergoni´ e,
BORDEAUX; P Strauss STRASBOURG; J Godinot REIMS;
Val d’Aurelle, MONTPELLIER; F Baclesse, CAEN; P Cal-
mette, MARSEILLE; A Vautrin, NANCY; R Gauducheau,
N A N T E S ;G FL e c l e r q ,D I J O N ;CR e g a u d ,T O U L O U S E ,a n d
Institut Curie (PARIS & ST CLOUD).) This protocol re-
cruited its ﬁrst patient in March 2009 and concluded patient
recrual in June 2011. The primary objective of this trial is to
assesswhethertheadditionofcetuximabtostandardtherapy
will impact on DFS at 18 months. Secondary objectives are
the analyses of genetic and protein biomarkers which may
predict response to therapy. Patients have not been screened
upfront as regards to pathway activation or downstream
mutations but biological assessments are ongoing. Hopefully
we shall be able to discern biological patterns that are
associated with response or progression in cervical cancers
in the near future which will allow us to plan new trials
accordingly.
2.4.StandardofCareandOngoingTrialsforPatientswithVery
Advanced (Stage IV) or with Recurrent Disease. Present op-
tions for the management of stage IV disease consist of pal-
liative therapy including chemo-radiation to the pelvis if
technically feasible, which is preceded or followed by more
chemotherapy. For practical reasons these two settings are
frequently regrouped in clinical trial protocols. There are se-
veral shortcomings: ﬁrstly, in the recurrent situation there is
blood vessel ﬁbrosis as a result of previous radiotherapy, de-
creasing drug availability at the tumour site. Secondly, these
tumoursareinherentlyresistanttoradiotherapyandnothig-
hlysensitivetochemotherapyandnewertreatmentstrategies
are desirable.
A series of ongoing or recently closed phase 1 and phase
2 trials in late stage disease which explore chemotherapy in
association with targeted therapies or targeted therapies
alone were discussed at the recent IGCS meeting in Prague,ISRN Oncology 3
October 2010 (Table 1). A number of targeted agents either
as single drugs or in association with another biological
agent or chemotherapy are being assessed in solid tumours
not otherwise speciﬁed and include angiogenesis, Braf, mtor,
akt,mek,notchinhibitors,amongothers(http://www.cancer
.gov/cancertopics/types/cervical).
3.TrialsinAdvancedCervicalCancersBasedon
Tumour Biology
3.1. Where Is the Cervical Tumour’s Achilles Heel? Advanced
cervical cancer is a relatively rare disease in developed coun-
tries. Cervical cancer biopsies, albeit of easy access, are not
available in large numbers. At this stage the three dominant
targets under scrutiny for innovative cervical cancer treat-
ments are the EGFR pathway, angiogenesis inhibition, and
anti-HPV vaccines. This may rapidly change as knowledge of
interactions between pathways develops.
There is to our knowledge no published data on repre-
sentative series with in-depth exploration of EGFR copy nu-
mbers, protein expression, on polymorphisms, activating
mutations or truncations. There is presently no information
on how any of these alterations could relate to response to
EGFR inhibitors. Assessing the activity (or lack of activity) of
an antibody targeting the extracellular domain of the recep-
tor may not be informative in the absence of knowledge on
downstream molecular activating mutations, such as ras/raf,
PI3K, and activations of mek, akt, mTor, and so forth. Over
expressionofEGFR,frequentlyassessedonlybyIHC,iscom-
monly seen in 2/3 of cervical tumour samples. Retrospective
data on a consecutive series with long term followup from
the Charit´ e Hospital in Berlin [9] did detect correlations
with outcome following radiotherapy and/or surgery but
their data suggested that EGFR (HER1) overexpression was
associated with a favourable outcome (P = 0.006) Concom-
itant overexpression of HER2 or HER3, favourite heter-
odimeric binding partners for HER1 was interestingly highly
signiﬁcantly associated with a poor prognosis (P = 0.006).
Data on phosphorylation status was not available. None of
these patients treated in the 90s had received an anti-EGFR
inhibitor, and virtually none of these patients had received
any chemotherapy at all. In a more recent publication, No-
ordhuis et al. [10] evaluate the prognostic impact of an
activatedEGFRpathwayasmeasuredbyIHCtestingofphos-
phorylated EGFR (19,7%), AKT (4,1%), PTEN (34,1%), and
ERK (29,2%) on prognosis. The study is based on pretreat-
ment samples of a population of 375 stage Ib-IVa cervical
cancer patients treated with standard chemoradiation. The
authors report that membrane EGFR (35,3%) staining was
inversely correlated with PTEN staining. Membrane staining
of EGFR correlated with cytoplasmic staining of pEGFR
and both were independent predictors of poor response to
chemoradiotherapy. Positive staining was deﬁned as 2-3
positive staining in at least 10% of tumour cells. No data on
hetero dimeric binding partners was reported and there has
been no signiﬁcant exploration on genetic ampliﬁcations of
EGFR, PI3K and so forth. to our knowledge.
Tumourgrowthandinvasionisdependentonbloodsup-
ply which makes angiogenesis inhibition one of the corner-
stones of cancer treatment. But angiogenesis may not be an
important target if the angiogenesis inducing mechanism is
eﬀectively targeted as suggested by dual targeting approaches
discussed earlier. The vascular endothelial growth factor
(VEGF) and receptor family is upregulated in conditions of
hypoxia, and in particular by hypoxia inducible factor 1.
HIF1α in turn is stimulated by HPVs as well as by activated
membrane tyrosine kinase receptors such as EGFR and
IGF1R. HIF1α has also been shown to be induced by apopto-
sis. There is furthermore ample evidence that angiogenesis is
induced by members of the PIK3/mTOR pathway [11–14]a s
wellasbyoncogenicpapillomavirusgenesE6andE7[15,16]
themselves. Single and double targeting strategies should be
helpful to discern the need to target angiogenesis speciﬁcally,
beyond the targeting of the immediate angiogenesis causing
mechanism.
More than 90% of cervical cancers bear one or more high
risk HPV types and have activation of viral E6 and E7 genes
and consequent loss of RB [17] and p53 [18] function, lead-
ing to a loss of the capability to undergo apoptosis as well as
to enhanced telomerase activity [19]. HPVs thus encode the
two tumour-speciﬁc oncoproteins E6 and E7 that act syner-
gistically to maintain the malignant phenotype [20–23]. pRB
degradation by E7 prevents its binding to E2F which in turn
regulates expression of genes involved in progression to the S
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like kinases (Plks) are involved in the assembly and dynamics
of the mitotic spindle apparatus and in the activation and
inactivation of CDK/cyclin complexes. Inhibitors of Plks are
being developed by pharmaceutical companies and may
prove of interest in cervical cancer treatment [24, 25]. How-
ever, tumorigenesis can be induced by either overexpression
or downregulation of Plks, suggesting that the level of Plk
has to be tightly regulated, reﬂecting its critical role in mi-
totic progression. Excessive Plk1 will override the mitotic
checkpoint amplify the centrosome abnormally, and chro-
mosomes will segregate without proper alignment or unequ-
ally. Insuﬃcient Plk1 will also lead to mitotic delay and im-
proper separation of chromosomes [26–28]. In both scenar-
ios,aneuploidy andtumorswilloccurandgeneticalterations
in the EGFR-PI3K pathway may be secondary events.
On the positive side, the HPV proteins E6 and E7 can act
as tumor antigens and elicit a favourable immune response
in which speciﬁc T cells play a critical role in the control and
elimination of the HPV infection. The virus-speciﬁc inter-
feron-γ-producing CD4+ cells and CD8+ cytotoxic T lym-
phocytes (CTLs) are able to recognise the oncoproteins E6
andE7andcontributetotheviralelimination[29–31].How-
ever, in case of an uncontrolled persistent infection with a
high-risk type HPV, the expression of the viral oncopro-
teins E6 and E7 contributes to the development of cervi-
cal (pre)malignancies. Apparently, the spontaneous HPV-
speciﬁc T cell response failed in these patients and there is
no or only a negligible expansion or activation of the proper
HPV16-speciﬁcCD4+ andCD8+ Tcells[32–34].Combining
current treatment strategies such as (chemo)radiotherapy4 ISRN Oncology
Table 1: Ongoing trials with targeted agents.
Products Trial
1 CDDP-Paclitaxel versus Topotecan-Paclitaxel ± bevacizumab GOG 204
2 Poly tki (pazopanib) versus EGFR/HER2 dual inhibitor (lapatinib) VEG 105281
3 VEGF and FGF2 inhibitor: Brivanib 227G
4 EGFR inhibitor erlotinib GOG 227 D
5 EGFR-targeted antibody cetuximab GOG 227 E
6 EGFR inhibition by cetuximab + CDDP GOG 76DD
7 Vaccine: listeriolysin O E7 fusion peptide: ADXS11: GOG 285
8 G1 checkpoint modulation, MK1775∗, inhibitor of Wee1 kinase activity GOG 265
9 Treatment with oncolytic viruses: PV701∗∗ PV701
10 Farletuzumab and folate receptor antibody coupled to vinca drug∗∗∗
∗Inhibitor of Wee 1 kinase activity promotes apoptosis when p53 is null.
∗∗Targets defect in interferon pathway (pathway disabled by HPV E6 and E7).
∗∗∗Folate receptor expressed in 1/3 of (most aggressive) cervical cancers.
or chemotherapy singly in association with immunotherapy
could oﬀer a novel approach for such patients. The ration-
ale for exploring these combined treatments is the positive
immune system stimulation demonstrated by several chem-
otherapeutic agents. In addition, preclinical data have shown
promising results with therapeutic vaccines. The safety and
immunogenicity of a synthetic long peptide E6/E7 HPV 16
vaccine was established in a phase 1/II trial in women with
recurrent cervix carcinoma [35]. Similar data have been
achieved with a viral vector based vaccine and [36]. Clinical
trials are currently ongoing in preinvasive CIN3 as well as in
cervical cancer patients using either peptide-based vaccines
or mutated E6 and E7 gene sequences in a poxviral vector.
Furthermore, the combined immunostimulatory eﬀect of
chemotherapy with long peptide HPV vaccination is being
tested in an ongoing clinical trial.
3.2. Thoughts on Therapeutic Prospects
3.2.1. Epithelial Growth Factor Receptor Tyrosine Kinase.
EGFR is overexpressed in more than half of all cervical can-
cers and its phosphorylated form is a dominant feature in
20% [10], suggesting that receptor EGFR blockage remains
a promising target. Strategies towards EGFR inhibition in
advanced and recurrent cervical cancers by either anti-EGFR
antibodies (cetuximab) or by small molecule tyrosine kinase
inhibitors(geﬁtinib,erlotinib,andlapatinib)areongoingbut
have not yet been conclusive. Reasons for the absence of
a major clinical breakthrough may be multiple. The absence
of the molecular target in nonscreened patients, the presence
of downstream activating mutations, the high degree of re-
sistance to standard therapy in the advanced setting, and
the redundancy in pathway activations may limit clinical re-
sponses to distinct molecular phenotypes. Data from head
and neck (H&N) cancer biopsies suggested that high EGFR
genecopynumber(Fish+)wasassociatedwithasigniﬁcantly
poorer outcome (review in expert opinion: [37]). It is un-
certainwhetherresultsonEGFRfunctioninH&Ncancercan
be extrapolated to cervical cancer; however, both are squa-
mous type carcinomas and both have an HPV-related aeti-
ology, suggesting that there might be activation of common
molecular features. The response pattern to EGFR inhibitors
in H&N tumours also remains controversial since low to
moderate IHC staining for EGFR expression [37] was shown
to correlate better to treatment than high EGFR expression.
It was hypothesized that the dosage of anti-EGFR inhibitors
may not have saturated the receptor in high expressing tum-
ours and further studies are warranted. Cetuximab, an anti-
bodytargetingmembraneEGFR,wasshowneﬃcientinimp-
roving the long-term survival of patients in association with
radiotherapy [38, 39] and is approved as an active drug in
H&N tumours.
EGFRinhibitionalsoremainsaprivilegedtargetofinves-
tigations in cervical tumours, based on the link between
EGFR activation and resistance to radiation and platinum-
based chemotherapy [10]. While EGFR is activated by phos-
phorylation in 20% of cervical cancers [10], no mutations
have been demonstrated so far to our knowledge, which
is very diﬀerent from lung cancer which harbours close to
20% (559/2880) mutations in the EGFR kinase domain [40].
EGFR variant III is a predominant feature of glioblastomas
[41] and has been associated with radiation resistance and
hypoxiatolerancetoourknowledge[42].Nodataisavailable
on EGFR variant III in cervical cancer. The prediction of a
responsetoEGFRtargetedtherapyincervicalcancerremains
a matter of debate since no precise molecular studies are
available. Consequently, no decisive results have been achie-
ved in early trials of nonselected patients with late stage
disease (GOG 76-DD). Solid predictive markers of response
areneeded[43].Othermembranereceptorsma ybeactivated
in the presence of HPV infection such as hepatocyte growth
factor and c-met [44] or insulin-like growth factor receptors
[45].
Diﬀerent drugs that target EGFR show more or less clin-
ical activity depending on the state of the molecular target.
Erlotinib performed best in lung cancers with high levels of
EGFR activation and activating mutations in the kinase do-
main [46] .T h e r ei sn oe v i d e n c eo fa c t i v a t i n gm u t a t i o n si n
the EGFR in cervical cancer to our knowledge. Lapatinib in
breast cancer was active predominantly in the presence of
phosphorylated EGFR and HER2 while Herceptin is active in
breast cancers with increased copy number of HER2 (Fish).ISRN Oncology 5
A nuclear translocalization mode of EGFR has recently been
reported in a variety of cancer cell types [47], and the eﬀect
of cetuximab on nuclear EGFR has been investigated with
variable results [48, 49]. Acquired resistance to cetuximab
has been linked to increased levels of nuclear EGFR in lung
cancer[48]whilelapatinibsupposedlyinhibitsnucleartrans-
location of both EGFR and HER2 [50]. Nuclear EGFR, be-
yond its kinase function, is thought to have functions in
gene regulation and in protein-protein interactions [47]. It is
supposedly implicated in a number of processes, including
DNA repair and resistance to DNA-damaging radiation and
alkylating anticancer agents. EGFR nuclear entry was sug-
gested to be blocked by lapatinib [50] and the Src family
kinase inhibitor, dasatinib [48]. Celecoxib has been shown to
inhibit radiation-induced nuclear EGFR transport [51]. The
ability of nuclear EGFR to enhance expression of iNOS [52]
and in particular Aurora Kinase [53] is challenging and
worth further assessments. Equally, EGFR inhibition togeth-
er with apoptosis inducing agents may have synergistic anti-
tumor eﬀects [54]. These observations provide a rationale
for selecting novel combination treatments that overcome
nuclear EGFR-mediated therapeutic resistance, but these
mechanisms need to be documented in cervical cancer bio-
psies and tested in preclinical xenograft studies.
3.2.2. PI3Kinase/PTEN and Ras/Raf Pathways. While precli-
nical studies on cell lines suggested an added beneﬁt of com-
bining cetuximab with cisplatin and radiotherapy, as mea-
sured by decreased MAPK and AKT phosphorylation, results
were independentofthe level ofEGFRexpression.I nso me,b u t
not all, cervical cancer cell lines a beneﬁt was seen in com-
biningcetuximabwithananti-TKI,ananti-MEK1/2,oreven
with trastuzumab suggesting that targeting EGFR alone may
not be enough.
Recent laboratory evidence using colorectal cancer cell
lines suggested that expression status of EGFR ligands (am-
phiregulin and epiregulin mRNAs) might need to be evalu-
ated as dynamic predictors of response in KRAS wild-type
(WT) patients receiving cetuximab-(CTX-) based therapy.
Thetranscriptionalcontroloftheepithelial-to-mesenchymal
transition(EMT)bykeratins,focaladhesionsignalling(inte-
grins), and EMT-inducing cytokines such as TGFβ as well
as the upregulation of the epithelial markers E-cadherin has
also been thought to be predictive and worth further as-
sessments [55]. Other downstream eﬀectors, such as Cox-2
overexpression [56], warrant further exploration. Germ-
line polymorphisms for EGF, EGFR, Cox2, Cyclin D1, and
FCGR2Amayalsobesigniﬁcantpredictivemarkersfortreat-
ment response in lung cancer [57], but data from patients
with cervical tumours treated with EGFR inhibitors is crit-
ically needed. The detection of a constitutively activating
polymorphism at codon 655 of HER2 has been described
[58] to be speciﬁcally associated with advanced carcinoma of
the uterine cervix. The same authors also showed that pa-
tients bearing the CCND1 A/A and A/G genotypes (of cyclin
D1) displayed a 1.811-fold increased risk of cervical cancer
(95% CI = 1.150–2.852, P = 0.0098).
3.2.3. Angiogenesis. Cervical tumours are frequently highly
vascular, bleeding spontaneously, and on minor contact, and
the addition of antiangiogenic agents has consequently been
tested in a series of clinical trials. Bevacizumab in associa-
tion with ﬁrst-line radiochemotherapy in untreated locally
advanced cervical cancer patients was well tolerated and is
currently being evaluated in several phase 2 trials designed
to test the therapeutic eﬃcacy in association with chemo-
radiation (RTOG 0417) as well as in combination with to-
potecan and cisplatin as ﬁrst-line therapy for recurrent or
persistent cervical cancer (GSK 107278). A phase III trial is
ongoing testing the value of bevacizumab in association with
two chemotherapy doublets, (NSC 708465), and the results
are eagerly awaited.
3.2.4.AngiogenesisandEGFRInhibitionCombined. Basedon
the assumption that cervical cancer is heavily dependent on
EGFR activation and on angiogenesis (in turn caused by
EGFR activation and HPV infection as well as by the hypox-
ia-induced VEGF), a phase II trial was designed to compare
a multitarget TKI and antivascular agent (pazopanib) and
an oral inhibitor of activated HER1 and HER2 (lapatinib).
Eachagentwasgivenaloneorincombinationinadvancedor
recurrent cervical cancer patients, not previously selected on
the basis of molecular assessments. Pazopanib proved overall
superior to lapatinib. Pazopanib improved PFS (hazard ratio
(HR), 0.66; 90% CI, 0.48 to 0.91; P = 0.013) and OS (HR,
0.67; 90% CI, 0.46 to 0.99; P = 0.045), and, interestingly, a
negative interaction between agents was suggested in the
combination arm, but complete dosage of both drugs could
not be achieved due to toxicity [59]. A similar negative cor-
relation through the addition of cetuximab to bevacizumab
in metastatic colorectal carcinoma resulted in a signiﬁcantly
shorter progression-free survival when both agents were
combined [60]. Since angiogenesis induction is enhanced
by both inappropriate HPV eﬀects on p53 and RB as well
as by EGFR pathway activation it might be useful to assess
countering HPV activity and EGFR pathway activation in
preclinical trials.
3.2.5. Immunological Targets. In preclinical experiments, a
prerequisiteforsuccessfulapplicationoftherapeuticvaccines
hinges on eﬀective induction of eﬀector T-cell responses.
Recently,ahighlyimmunogenicsyntheticlongpeptide(SLP)
vaccine,consistingoflongoverlappingpeptidesoftheE6and
E7oncogenicproteinsofHPV,hasbeendevelopedandtested
clinically. The vaccine elicited strong and broad HPV16-
speciﬁc CD4+ and CD8+ T-cell responses in patients with
cervical cancer without toxicity beyond grade 2 and was well
tolerated by patients. The immune response did; however,
not yet result in measurable clinical beneﬁcial eﬀects, and
the therapy should be explored further [35, 61]. Markers
of the integrity of an immune response that may result in
clinical beneﬁt are critically needed. It is of interest to note
that,incell-linemodels,theactivationofPI3KinLangerhans
cells was associated with an impaired immune response due
to repression of genes related to immune function [62]
suggesting that PI3K pathway activation may render vaccine
strategies ineﬀective. That the immunological approach is6 ISRN Oncology
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Figure 1: Pathway convergences and intercept nodes. This ﬁgure serves to illustrate somewhat the complexity of pathway interactions; it is
not meant to be an exhaustive documentation of interactions. It is based on the references in this paper.
not futile is demonstrated by the recent ﬁndings showing
thatvaccinationwiththisvaccineinpatientswithhigh-grade
vulvar intraepithelial neoplasia achieved a strong virus-spe-
ciﬁc T-cell immunity and was indeed associated with a com-
plete regression of neoplastic lesions in approximately half of
the patients [63] .S i m i l a rd a t ai sd o c u m e n t e di nC I N 3p r e -
neoplastic lesions using a diﬀerent vaccine [36] and a phase
3 trial is ongoing with this reagent.
It is reasonable to assume that chemotherapy or targeted
therapies may contribute to the successful application of im-
munotherapy, for instance, by providing an opportunity for
eﬀective induction. It is likely that timing of the immuno-
therapy in addition to chemotherapy is crucial to optimally
utilize the immunostimulatory aspects of chemotherapeu-
tics, although currently the data from treated patients are
limited.
3.2.6. DNA Repair Pathway. The single constant factor in
cervical cancer treatment for the last 20 years is the use of
platinum salts and radiotherapy, which suggests that somatic
abnormalities of DNA repair enzymes may be prevalent
in these tumours. To date there is little information on
pretreatment DNA repair abnormalities to our knowledge.
If a preexisting defect in DNA repair enzymes in cervical
cancers was documented, this could lead to the use of PARP
inhibitors in selected advanced and recurrent tumours. In
evaluating gene expression changes as a result of chemoradi-
ation, Klopp et al. identiﬁed modiﬁcations in genes involved
in DNA repair (including DDB2, ERCC4, GADD45A, and
XPC), in addition to signiﬁcant changes in cell-to-cell signa-
lling pathways such as insulin-like growth factor-1 (IGF-1),
interferon, and vascular endothelial growth factor signalling
[64]. Relations between pretreatment expression of compo-
nents of the DNA damage recognition complex (Ku70 and
Ku80 protein levels) and radiation sensitivity as well as sur-
vivalhavebeeninvestigatedinthepast[65,66]andmayneed
further attention.
3.2.7. Multiple Pathway Activation. Based on complete exon
sequencing in a variety of tumours, it was suggested by B.
Vogelstein at the 2010 AACR meeting that most solid tum-
ours have alterations in more than one pathway.T w e l v e
dominant pathways were identiﬁed (Figure 1): PI3K/PTEN,
ras/raf,G1/Stransition,TGFβ/smad,Wnt/betacatenin,Hed-
gehog, HIF-1a, Jak/stat, notch, DNA damage control, apop-
tosis, and adhesion.
None of these pathways acts in isolation, and more than
one pathway may need inhibiting to achieve an eﬀectiveanti-
tumourresponse.Converselyblockingonepathwaymayren-
der double targeting obsolete if the second pathway is under
the control of the ﬁrst. There is also growing evidence for
convergences between pathways.
(i) Convergence between Wnt/β-catenin and EGFR sig-
nalling has been documented by several authors.
Wnt/β-catenin overexpression was shown to activateISRN Oncology 7
signalling via EGFR, while EGFR can form a complex
with β-catenin in cancer cells thereby increasing
invasion and metastasis [67]. In developmental mod-
els, Wnt and EGFR act together and they may be
crosstalkingdiﬀerentlydependingoncontextandcell
model [68]. It has been suggested in breast cancer
models that interference with WNT signalling at the
ligand-receptor level in combination with other tar-
geted therapies may improve the eﬃciency of cancer
treatments [67, 69]. Dual targeting of EGFR and
angiogenesis pathways was not synergistic in early
trials of cervical cancers, but the population was too
small and the tolerance of full dose for either path-
wayinhibition wasnotsatisfactorytodrawvalidcon-
clusions. It has been suggested from breast cancer
studiesthatlapatinibactsonlyonthephosphorylated
form of EGFR (in the presence of wild-type ras/raf)
which would mean that the number of patients pot-
entially able to beneﬁt represents at best 20% of the
total population.
(ii) There is ample literature data on a convergence of
the PI3K/PTEN pathway with the angiogenesis path-
way [11–14]. Direct inhibition of PTEN gene expres-
sion [70] via siRNA knockdown experiments was
shown to cause upregulation of VEGF secretion, with
increasedangiogenesis,cellularproliferationandinv-
asiveness [71]. A dual combined action within the
PI3K/PTEN pathway by restoring PTEN and inhibit-
ing PI3K synergistically suppressed glioblastoma gro-
wth in preclinical trials [72].
(iii) Emerging data suggest that HPV may directly stim-
ulate VEGF production through upregulation of the
E6 oncoprotein [15, 16].
(iv) Cells interact with their microenvironment. Trans-
forming growth factor-β was shown to activate PI3K
in HER2 overexpressing breast cancer cells, to engage
stromal and endothelial cells in the tumour environ-
ment [73] and to cause Herceptin insensitivity.
(v) Persistent hedgehog (Hh) activation may also coop-
eratewithotheroncogenicproducts,suchasmutated
K-RAS and crosstalk with diﬀerent growth factor
pathways,includingtyrosinekinasereceptors,suchas
epidermal growth factor receptor (EGFR), Wnt/beta-
catenin, and transforming growth factor-beta (TGF-
beta)/TGF-beta receptors [74]. The hedgehog path-
way may also be induced by Hif-1α [75].
There is recent data with dual targeting showing a sustained
beneﬁt in some patients. In metastatic head and neck tum-
ours treated by erlotinib in association with bevacizumab,
complete responses were associated with expression of pu-
tative targets in pretreatment tumour tissue [76]. But these
early data must be viewed with caution due to the possibility
of negative interactions as was suspected for EGFR inhibitors
and angiogenesis and multi-TKI targeting, [59, 60]e v e n
though the population was not screened for target expres-
sion.
3.3. Future Strategies to Achieve a “Best Fit” between Optimal
Clinical Information with Minimal Patient Exposure?
3.3.1. Deﬁnition of Molecular Markers of Pathway Activation
and of Biomarkers Predictive of Response. Several areas of
investigations are currently ongoing in many institutions
with the aim of precisely deﬁning the biological target for a
given drug or drug combination.
Genetic Mutations. There is little available data on genetic
mutations in cervical cancer specimens. While EGFR is fre-
quently activated and constitutes a primary target, there is
to our knowledge no evidence of EGFR gene mutations. The
following mutations in cervical cancer samples have been re-
gistered in the Sanger database by order of frequency: STK11
(serine threonine kinase) (29/201: 14%), Hras (23/263: 9%),
Kras (46/636: 7%), PIK3CA (25/255: 10%), CDKN2A (23/
267: 9%); in addition loss of PTEN has been documented in
16 cases. Mutations in small numbers of a variety of other
genes, CTNNB1 (8), FGFR (6) Braf (5), TP53 (3), Nras (2),
RB1 (2) FBXW7 (1) BRCA2 (1), and MSH2 (1), have also
been reported. The STK/LKB1 gene encodes a ubiquitously
expressedserine/threoninekinasethatismutatedinmultiple
sporadic cancers and plays a role in cell growth, cell cycle
progression, metabolism, polarity and migration. It is sug-
gested that LKB1 and its neighbouring genes are frequently
deregulated in primary cervical cancers and that multiple
fusion transcripts are generated which may be driven by the
c19orf26 promoter [77].
None of these mutations is predominant in a large fra-
ctionofthepopulation.If,hypothetically,thepresenceofany
one of these mutations was exclusive and if any mutation was
suﬃcient to circumvent EGFR signalling, then EGFR inhibi-
tion might, at worst, be inoperative in 50% of patients. This
is unlikely to be the case, but strategies to diagnose and over-
come resistance to membrane receptor targeting are under
exploration. In breast cancer cells, the lack of a response to
membrane receptor inhibition was related to persistent
downstream activations of PI3K (pAKT), mTOR(pS6K) and
MAPK (pERK), (San Antonio Breast Cancer Conference
2010: O’Brien A: P4-01-06). The synergistic therapeutic ef-
fectofadownstreaminhibitor(Rapamycin)ofPI3K/AKTto-
gether with membrane receptor inhibition has been docu-
mented in preclinical assessments, and these are now tested
inearlyclinicaltrials(SanAntonioBreastCancerConference
2010: Abu-Khalaf: A: P3-14-17). Similarly, the combined
use of src and MAPK inhibitors was shown to be capable
of overcoming resistance to membrane receptor inhibition
in selected patients (San Antonio Breast Cancer Conference
2010: Jegg A: P3-14-14).
For practical purposes, to make valid clinical decisions
in the future, we need solid biomarkers relevant for each
gain or loss of function at each step of the signalling net-
work. Computer-assisted calculations of the major signalling
pathways, and also of the “weaknesses” in the signalling8 ISRN Oncology
network might, guide us to double-target selected pathways
and increase treatment eﬃcacy by synthetic lethality.
Activated Phosphoprotein Status by RPPA (Reverse Phase
Protein Array). RPPA consists of analysing microdeposits of
protein lysates on a nitrocellulose coated slide. Up to a thou-
sand samples can be processed in a single analysis, allowing
excellent control of variability between patients. The mini-
mal amount of material needed is 5ng of protein sample.
RPPA allows speciﬁc assessment of the activation (by phos-
phorylation)oftyrosinekinasepathwaysaswellasangiogen-
esis, apoptosis, adhesion, the NFkB pathway, and the Jak/Stat
pathway. Results are based on a comparative analysis using
both a speciﬁc validated antibody for the protein of interest
and, in parallel, antibody for the phosphorylated form of the
protein. Valuable innovative information on activation of
sig-nalling pathways in the patients’ tumours, not only prior
to treatment but also according to their response to therapy,
can be obtained, allowing to “ﬁngerprint” the therapeutic ef-
fect and to establish robust predictive markers for treatment
response.
3.3.2. Therapies according to Tumour-Speciﬁc Alterations. A
great number of chemical and biological reagents are in
preclinical and clinical testing in multiple drug companies
and the majority of these drugs have been designed to show
activityinoneofBVogelstein’s(Figure 1)12majorpathways.
Many of the drugs in clinical testing (Table 2) that show a
preciselydocumentedactivityonwell-deﬁnedcelllinesanda
suﬃcientlygoodtolerabilityinearlyclinicalassessmentsmay
not prove of suﬃcient clinical interest as single agents and
might risk being prematurely terminated from development.
Drug development is costly, and there is a growing
trend to use intelligent drug combinations on molecularly
deﬁned tumours. There is increasing data showing positive
results of associations between chemotherapy and Parp
inhibitors in DNA-repair-deﬁcient cancers. Dual targeting
by mTOR inhibitors and geﬁtinib in lung cancer as well as
the demonstration of preclinical synergy between erlotinib
and metformin in cell lines through a robust reduction of
biomarkersrepresentedbyphosphorylatedEGFR,AKT,ERK
and S6 may pave the way for other drug associations (San
Antonio Breast Cancer Conference 2010 Lau: A: PD03-05).
The choice of reagents in cervical cancers still depends
on the deﬁnition of speciﬁcally activated pathway deregu-
lation which needs further assessments. Genetic or protein
biomarkers—tested before and after treatment—are cru-
cially needed to allow prediction of activity for each indi-
vidualpathwayabnormalityandpreparethewayformultiple
targeting in the future. Rigorous validation tests and inter-
laboratory controls are needed for most of the IHC assays on
patient samples as there may be much variability as a fun-
ction of sample preparation and of antibody provenance.
PTENlosshasbeenshowntobeassociatedwithdownstream
pathway activation and a recent publication comparing tech-
nical aspects and demonstrating the availability of a robust
PTEN assay [93] merits consideration.
Xenografts of cervical cancers are available at our centre
and will allow testing of single and dual targeting of in-
novative therapies after extensive characterization to be done
in parallel with the samples of tumours from the Cetuxicol
trial.
Of upmost importance will be the clinical monitoring of
activity. Early NMR or Pet scan evaluation (with RGD ﬂuci-
clatide) is slikely to be helpful, but foremost cervical cancers
canbebiopsiedbeforeandaftertherapeuticinterventionand
the loss of activation in a given pathway should be an ideal
early endpoint in future clinical trials.
3.3.3. Clinical Trial Design for Targeting Biological Path-
ways. Geﬁtinib, an anti-EGFR reagent, has been assessed
in association with chemotherapy in large phase III trial
designs with little or no demonstration of clinical beneﬁt
(INTACT 1&2 and others) while the same reagents, if given
in selected patients with speciﬁed molecular abnormalities
in their tumours, did show a major therapeutic impact
[94]. In lung cancer patients, response rates of 72% could
thus be demonstrated in the presence of the predictive exon
19 deletions or L858R mutations as compared to 10% in
patients with wild-type EGFR.
A classical randomized trial design is ideal if the
biological target is well deﬁned and present in the majority
of the patient population, which appears to be the case for
EGFR pathway activation or angiogenesis in cervical cancer.
This design is problematic if there is a great number of
interfering parameters (downstream activating mutations)
renderingmembranereceptorinhibitioninoperativeorifthe
targets can come in diﬀerent states (activated, overexpressed,
and mutated) and if diﬀerent mutations may mean diﬀerent
response patterns. In cervical cancer a number of possible
downstream genetic mutations are reported in the Sanger
database. The absence of a response to EGFR targeting in the
presence of activating ras or raf mutations has been shown
in colon cancers [95–97]. If each downstream mutation
prevents a clinical response via EGFR targeted inhibition,
EGFR inhibitors are unlikely to make a major breakthrough.
However the data that are available are from trials including
only patients with advanced or relapsed tumors who are
likely to harbor more than one molecular abnormality.
Questions as to the choice of one or more targeted
drugs in the presence of a complex set of alterations can
only be addressed as we gain experience with molecular
targeting in single settings (phase I) and in the presence
of validated and robust markers of activity (phase II with
biological endpoints). Vogelsteins’ suggestion at the 2010
AACR meeting was to target pathways rather than individual
molecules. At this stage the systematic molecular analysis of
tumors by pathways is in its infancy, as is the adptive trial
design necessary for personalized medicine. A promising
methodologicaldesignforsuchatrialcouldbesimilartothat
of the “BATTLE” trial in lung cancer presented by Kim at
the 2010 AACR meeting [98]. The strategy was to randomize
into 4 diﬀerent treatments in a ﬁrst instance, to be followed
by an adaptative design which allowed higher recruitment
into the treatment arms that had given best results in the ﬁrst
leg of the clinical trial.ISRN Oncology 9
Table 2: Potential biomarkers according to pathway.
Pathway activation Reagents Diagnostic or predictive bi-
omarkers under scrutiny
PI3K/PTEN∗
PI3K inhibitors: PI103, BGT226mTor inhibitors: temsirolimus,
everolimus, ridaforolimas
AKT inhibitors: perifosine, GSK690693 and MEK inhibitors
?p E R K
Ras/raf pathway∗∗
Ras inhibitors: tipifanib, lonafnaib
Raf inhibitor: sorafenib,PLX4032
MAPK inhibitor: AZD6244,XL518
tbd
HIF-1α (angiogenesis) Bevacizumab, VEG105281, Brivanib, Sunitinib, AZD2171
HIF1α inhibitor: Adaphostin Tbd
G1 checkpoint Checkpoint inhibitor: MK1775∗∗∗
∗∗∗∗? Retinoic acid and Topotecan
? p53, p63, p73
? Wee-1, Myt1, ChK1,
CDC2
Apoptosis∗∗∗∗∗ ? Anti HPV vaccine indicated here
? p53, p63, p73;
? Inactivation of p15
± RB,bcl-xl
DNArepair: homologous
recombination deﬁcient PARP inhibitors
? DNA damage control
deﬁciency/Homologous
recombination
BRCA2 mutation (rare)
Jak/stat ? PV-701 (oncolytic virus) targets interferon
pathway defects which are induced by HPV E6 and E7
? IL8 (−)
? B cell signature (+)
?Tr e g u l a t o r yc e l l s( −)
TGF β ? ?IL10, TGF β
Adhesion ? Tbd
Hedgehog BMS-83392, IPI 926, LDE225, LEQ 506, GDC-0449, PF
04449913, TAK 441, Tbd
Wnt/β Catenin∗∗∗∗∗∗
Wnt1, Wnt2: neutralizing antibodies AINS, Vit D
PKF115-584, PKF222-815, CPG049090
NSC668036
Oncolytic adenoviruses modiﬁed to target Tcf-β Catenin
Antisense Avi-4126 targets end product c-myc
Notch Neutralizing Antibodies against ligand Tbd, ? AKT
— Farletuzumab Folate receptor
— Folate receptor coupled to vinca drug Folate receptor
Neighboring cells Active on tumour micro-environment Tbd
Multi pathway inhibitors Pazopanib∗∗∗∗∗∗ Tbd
∗PIK3 ampliﬁcation or mutational activation or PTEN loss. Activation of the PIK3/AKT/mTOR pathway was associated with a worse prognosis and chem-
oresistance in cervical cancers [78].
“?” means not validated.
∗∗Ras/raf pathwayalterationsincolon cancer render thesetumoursresistantto anEGFRinhibitor.Rasinhibitorssuch asTipifanibor lonafanibdidnotshow
relevant clinical activity in phase II and III studies in various tumour types [79] and may be worth assessing again in single and dual targeting in selected
preclinicalmodels. ∗∗∗E6mediatedinactivationofp53upregulatesVEGFandangiogenesis. ∗∗∗∗Retinoicacidandtopotecanmaybeusefulintumourswith
checkpoint activation [80]. ∗∗∗∗∗There is evidence that human papillomavirus infection enhances phosphorylation of retinoblastoma protein and decreases
apoptosis in a particularly aggressive type of squamous cell carcinoma of the uterine cervix [20–23]. ∗∗∗∗∗∗Wnt/β Catenin inhibition: by antibodies [81–
83], AINS, [84–86], VitD3 [87], or small molecules [88–90] or oncolytic viruses [91]. Also antisense, molecule to end product c-myce [92].
4. Conclusion andPerspectives
Advanced cervical cancer remains a public health issue de-
spite the availability of preventive vaccines and population-
based screening. Preventive vaccines have become available a
few years ago, but they target a very young teenage patient
population with a delayed impact on cervical cancer due to
the peak of cervical cancer incidence at ages 45–55. Further-
more, screening and vaccines are not widely available in
the countries which are most in need, while the vaccine
acceptance is now being challenged in some richer Western
European countries.
Cervical cancer is accessible to repeated biopsies which
make the screening for a series of molecular abnormalities
before and after a strategic intervention possible. Treatment
strategies can be designed according to speciﬁc molecular
proﬁles. We do presently not know which speciﬁc gene mut-
ations are associated with which pathway activation. We
do not know which EGFR alterations or which EGFR/
ras/raf/PI3K pathway alterations correlate with cetuximab10 ISRN Oncology
activityorineﬃcacy,butthepresenceofafunctionalreceptor
in the absence of a downstream constitutive activation may
prove to be a minimal requirement. The EGFR PI3kinase
pathway deregulations certainly need further studies as do
cyclins and cyclin-dependant kinases.
Castellino and Durden [99] put forward a hypothesis
according to which, instead of inhibiting one single cell sur-
face receptor, such as VEGFR2 with bevacizumab (Avastin),
therebyleavingasigniﬁcantnumberofreceptorsfreetopulse
angiogenic signals, a more eﬀective strategy may be to reg-
ulatesignallingthroughtargetinganinterceptnodewherecell
surface receptor signals converge (Figure 1) to transmit imp-
ortant signalling events within the cell and thereby bring a
coordinate control over multiple pathways. These intercept
nodes need deﬁning though with pre- and post therapeutic
molecular “footprinting” following single and double target-
ing agents.
There is a need to coordinate eﬀorts within national and
international groups to allow patient recruitment in a reas-
onabletimeframe,theaddedbeneﬁtbeing thatmultination-
al trials will also favour harmonization in standards of care.
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